nach oben

nächster Artikel Triple-negative breast cancer possibly transfor...

Tipp

Aktuelle Anforderungen an die Diagnostik bei chronisch myeloischer Leukämie

Zeitschrift:: Wiener Medizinische Wochenschrift > Ausgabe 21-22/2013

Autoren:: MD, PhD Univ.-Prof. DDr. Thomas Lion, PhD Dr. Gerald Webersinke, MD, PhD Univ.-Doz. DDr. Ulrike Kastner, PhD Univ.Doz. Dr. Christoph Seger, MD Univ.-Prof. Dr. Gerlinde Mitterbauer-Hohendanner, MD Univ.-Prof. Dr. Günther Gastl

Zusammenfassung

Qualitativ hochwertige Diagnostik spielt für die Überwachung des Therapieerfolgs bei Patienten mit chronisch myeloischer Leukämie eine entscheidende Rolle. Die Verfügbarkeit neuer Tyrosinkinase-Inhibitoren, die zu einem rascheren und tieferen Therapieansprechen führen, erfordert den Einsatz standardisierter und hochsensitiver Diagnostikmethoden, um ein optimales Monitoring der Patienten zu gewährleisten. In der vorliegenden Übersicht werden die aktuellen internationalen Diagnostikstandards und die zertifizierten Laboratorien in Österreich präsentiert.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Jetzt informieren

Quintas-Cardama A, Cortes J. Molecular biology of bcr-ABL11-positive chronic myeloid leukemia. Blood. 2009;113(8):1619–30 (Epub 2008/10/02).

Hehlmann R, Hochhaus A, Baccarani M, European L. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342–50 (Epub 2007/07/31).

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the ABL1 tyrosine kinase on the growth of Bcr-ABL1 positive cells. Nat Med. 1996;2(5):561–6 (Epub 1996/05/01).

O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl j Med. 2003;348(11):994–1004 (Epub 2003/03/15).

Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–61 (Epub 2009/03/14).

Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Educ Program. 2008:419–26 (Epub 2008/12/17).

Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or suboptimal response reliABL1y identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112(12):4437–44 (Epub 2008/08/22).

Radich JP. How I monitor residual disease in chronic myeloid leukemia. Blood. 2009;114(16):3376–81 (Epub 2009/08/08).

Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172–5 (Epub 2012/04/17).

10.

Onitilo AA, Engel JM. Managing relapse of CML using therapeutic imatinib plasma level. Clin Adv Hematol Oncol: H & O. 2009;7(11):763–7 (Epub 2010/01/16).

11.

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol: Offic J Am Soc Clin Oncol. 2009;27(35):6041–51 (Epub 2009/11/04).

12.

Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Dreyling M et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol: Offi J Eur Soc Med Oncol/ESMO. 2012;23 Suppl 7:vii72–7 (Epub 2012/11/20).

13.

Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096–102 (Epub 2012/03/27).

14.

Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, et al. Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. Crit Rev Oncol/Hematol. 2012;82(3):370–7 (Epub 2011/09/10).

15.

Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35 (Epub 2010/10/23).

16.

Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–70 (Epub 2010/06/08).

17.

Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123–9 (Epub 2011/12/14).

18.

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–9 (Epub 2010/06/08).

19.

Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197–203 (Epub 2012/06/16).

20.

Tibes R, Mesa RA. Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques. Leuk Res. 2012;36(6):664–71 (Epub 2012/03/31).

21.

Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208–15 (Epub 2011/05/13).

22.

Rumpold H, Webersinke G. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia – is it all BCR-ABL1? Curr Cancer Drug Targets. 2011;11(1):3–19 (Epub 2010/11/11).

23.

Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J, et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes, Chromosomes & Cancer. 2007;46(5):494–9 (Epub 2007/02/22).

24.

Association for Clinical Cytogenetics. Chronic myeloid leukaemia & myeloproliverative neoplasms best practice guidelines. 2011;v1.00.

25.

Grand FH, Burgstaller S, Kuhr T, Baxter EJ, Webersinke G, Thaler J, et al. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res. 2004;64(20):7216–9 (Epub 2004/10/20).

26.

Kelly JC, Shahbazi N, Scheerle J, Jahn J, Suchen S, Christacos NC, et al. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL11/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet. 2009;192(1):36–9 (Epub 2009/06/02).

27.

Jabbour E, Kantarjian H, O’Brien S, Shan J, Quintas-Cardama A, Faderl S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118(17):4541–6; quiz 759 (Epub 2011/08/02).

28.

Quintas-Cardama A, Cortes JE, Kantarjian HM. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications. Cancer. 2011;117(23):5261–70 (Epub 2011/05/21).

29.

Cortes J, Quintas-Cardama A, Jabbour E, O’Brien S, Verstovsek S, Borthakur G, et al. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirABL1e endpoint? Clin Lymphoma, Myeloma Leuk. 2011;11(5):421–6 (Epub 2011/08/13).

30.

Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood. 2001;98(6):1732–8 (Epub 2001/09/06).

31.

Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S, et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol: official J Am Soc Clin Oncol. 2010;28(16):2748–54 (Epub 2010/05/05).

32.

Huh J, Jung CW, Kim JW, Kim HJ, Kim SH, Shin MG, et al. Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia. Ann Hematol. 2011;90(11):1255–64 (Epub 2011/03/09).

33.

Al Achkar W, Wafa A, Mkrtchyan H, Moassass F, Liehr T. A rare case of chronic myeloid leukemia with secondary chromosomal changes including partial trisomy 17q21 to 17qter and partial monosomy of 16p13.3. Mol Cytogenet. 2010;3:6 (Epub 2010/03/18).

34.

Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118(26):6760–8 (Epub 2011/11/01).

35.

Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012;120(4):761–7 (Epub 2012/06/14).

36.

Meggyesi N, Kozma A, Halm G, Nahajevszky S, Batai A, Fekete S, et al. Additional chromosome abnormalities, BCR-ABL1 tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients. Acta Haematol. 2012;127(1):34–42 (Epub 2011/10/19).

37.

Kim TD, Turkmen S, Schwarz M, Koca G, Nogai H, Bommer C, et al. Impact of additional chromosomal aberrations and BCR-ABL1 kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica. 2010;95(4):582–8 (Epub 2009/12/18).

38.

Virgili A, Brazma D, Reid AG, Howard-Reeves J, Valganon M, Chanalaris A, et al. FISH mapping of Philadelphia negative BCR/ABL11 positive CML. Mol Cytogenet. 2008;1:14 (Epub 2008/07/22).

39.

Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, et al. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 2011;117(25):6793–800 (Epub 2011/03/31).

40.

Al Achkar W, Wafa A, Mkrtchyan H, Moassass F, Liehr T. Novel complex translocation involving 5 different chromosomes in a chronic myeloid leukemia with Philadelphia chromosome: a case report. Mol Cytogenet. 2009;2:21 (Epub 2009/11/11).

41.

Albano F, Anelli L, Zagaria A, Coccaro N, Casieri P, Rossi AR, et al. Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Mol cancer. 2010;9:120 (Epub 2010/05/27).

42.

Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007;110(7):1509–19 (Epub 2007/08/19).

43.

Sun J, Yin CC, Cui W, Chen SS, Medeiros LJ, Lu G. Chromosome 20q deletion: a recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission. Am J Clin Pathol. 2011;135(3):391–7 (Epub 2011/02/26).

44.

Fabarius A, Haferlach C, Muller MC, Erben P, Lahaye T, Giehl M, et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica. 2007;92(6):834–7 (Epub 2007/06/07).

45.

Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL1 fusion mRNAs in haematological disorders. Leukemia. 1994;8(1):186–9 (Epub 1994/01/01).

46.

Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL11 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(3):232–8 (Epub 2011/11/10).

47.

Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, et al. Responses to second-line tyrosine kinase inhibitors are durABL1e: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood. 2012;119(8):1838–43 (Epub 2011/12/17).

48.

Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758–65 (Epub 2010/08/04).

49.

Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011;118(6):1622–31 (Epub 2011/06/10).

50.

de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol: official J Am Soc Clin Oncol. 2008;26(20):3358–63 (Epub 2008/06/04).

51.

Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26(29):4806–13 (Epub 2008/07/23).

52.

Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, et al. Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wien Klin Wochenschr. 2008;120(21–22):697–709 (Epub 2009/01/01).

53.

Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, et al. Nilotinib is associated with a reduced incidence of BCR-ABL1 mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013;121(18):3703–8 (Epub 2013/03/19).

54.

Preuner S, Denk D, Frommlet F, Nesslboeck M, Lion T. Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL1 tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR). Leukemia. 2008;22(10):1956–61 (Epub 2008/04/25).

55.

Preuner S, Mitterbauer G, Mannhalter C, Herndlhofer S, Sperr WR, Valent P, et al. Quantitative monitoring of BCR/ABL11 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. Eur J Cancer. 2012;48(2):233–6 (Epub 2011/10/01).

56.

Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol: Off J Am Soc Clin Oncol. 2004;22(5):935–42 (Epub 2004/03/03).

57.

Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14(21):7102–9 (Epub 2008/11/05).

58.

Davies A, Hayes AK, Knight K, Watmough SJ, Pirmohamed M, Clark RE. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leuk Res. 2010;34(6):702–7 (Epub 2009/12/17).

59.

De Francia S, D’Avolio A, De Martino F, Pirro E, Baietto L, Siccardi M, et al. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J Chromatogr B, Analyt Technol Biomed Life sci. 2009;877(18–19):1721–6 (Epub 2009/05/12).

60.

Streit F, Binder L, Hafke A, Brandhorst G, Braulke F, Haase D, et al. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. Ther Drug Monit. 2011;33(5):632–43 (Epub 2011/09/14).

61.

Gandia P, Arellano C, Lafont T, Huguet F, Malard L, Chatelut E. Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed? Cancer Chemother Pharmacol. 2013;71(2):531–6 (Epub 2012/11/28).

62.

Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022–8 (Epub 2008/02/08).

63.

Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496–9 (Epub 2006/12/29).

64.

Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, et al. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma. 2011;52(6):1024–9 (Epub 2011/04/06).

65.

Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–20 (Epub 2006/05/20).

66.

Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia. 2009;23(9):1537–44 (Epub 2009/05/01).

67.

Teng JF, Mabasa VH, Ensom MH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectABL1e gastrointestinal stromal tumors. Therap Drug Monit. 2012;34(1):85–97 (Epub 2012/01/05).

68.

Faber E, Friedecky D, Micova K, Rozmanova S, Divoka M, Jarosova M, et al. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol. 2012;91(6):923–9 (Epub 2012/01/11).

69.

Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(32):4017–25 (Epub 2012/08/29).

70.

Gotta V, Buclin T, Csajka C, Widmer N. Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes. Therap Drug Monit. 2013;35(2):150–67 (Epub 2013/03/19).

71.

Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Therap Drug Monit. 2009;31(5):579–84 (Epub 2009/09/05).

72.

Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, et al. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51(3):187–201 (Epub 2012/02/22).

73.

Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(3):406–15 (Epub 2010/12/18).

74.

Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):e75–87 (Epub 2010/09/03).

75.

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(14):2381–8 (Epub 2010/04/14).

76.

Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer. 2012;118(5):1181–91 (Epub 2011/11/01).

77.

Abbas R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol. 2013;71(1):123–32 (Epub 2012/10/12).

78.

Thienelt CD, Green K, Bowles DW. New and estABL1ished tyrosine kinase inhibitors for chronic myeloid leukemia. Drugs Today. 2012;48(9):601–13 (Epub 2012/10/04).

79.

Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‚real-time‘ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia. 2003;17(12):2318–57 (Epub 2003/10/17).

80.

Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using‚ ‚real-time‘ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia. 2003;17(12):2474–86 (Epub 2003/10/17).

81.

Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE, et al. Guidelines for the measurement of BCR-ABL11 transcripts in chronic myeloid leukaemia. British J Haematol. 2011;153(2):179–90 (Epub 2011/03/09).

82.

Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423–32 (Epub 2003/10/10).

83.

Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL1 transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37 (Epub 2006/03/09).

84.

Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23(11):1957–63 (Epub 2009/08/28).

85.

Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW, et al. DesirABL1e performance characteristics for BCR-ABL1 measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330–8 (Epub 2008/08/08).

Titel: Aktuelle Anforderungen an die Diagnostik bei chronisch myeloischer Leukämie
Autoren:: MD, PhD Univ.-Prof. DDr. Thomas Lion
PhD Dr. Gerald Webersinke
MD, PhD Univ.-Doz. DDr. Ulrike Kastner
PhD Univ.Doz. Dr. Christoph Seger
MD Univ.-Prof. Dr. Gerlinde Mitterbauer-Hohendanner
MD Univ.-Prof. Dr. Günther Gastl
Publikationsdatum: 01.11.2013
DOI: https://doi.org/10.1007/s10354-013-0239-8
Verlag: Springer Vienna
Zeitschrift: Wiener Medizinische Wochenschrift
Ausgabe 21-22/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Aktuelle Anforderungen an die Diagnostik bei chronisch myeloischer Leukämie

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Weitere Artikel der Ausgabe 21-22/2013

Buchbesprechung

Unclassified cardiomyopathies in neuromuscular disorders

Anorectal malignant melanoma in a hemorrhoidal nodule: a diagnostic and therapeutic problem

Cyclic vomiting syndrome in adults

Triple-negative breast cancer possibly transforming into malignant melanoma due to targeted therapy? A case report and review of literature